Smith & Nephew shares tumble on market slowdown fears
Friday 06 August 2004
Smith & Nephew, the FTSE 100 manufacturer of artificial hips and knees, saw £500m wiped from its market value yesterday after revealing a slowdown in its markets and a disappointing product launch.
The company's interim results were below even the most conservative forecasts, the first "miss" since Sir Christopher O'Donnell became chief executive and reshaped the historic medical supplier in 1998.
S&N'sshares plunged 52.5p to 481p, valuing the company at £4.5bn. Sir Christopher blamed a skittish market that "will jump at shadows" and said he was "confident" of matching the City's forecasts for the full year.
He said the main factor in the missed forecasts was poor sales of a new cream for ulcers, bed sores and burns. The supplier of S&N's previous product failed regulatory inspections and had to be replaced. "The new product has some slight clinical differences, and take-up has been slow," Sir Christopher said.
Sales in the US woundcare division were down a worse-than-expected 15 per cent. However, investors were also spooked by a slowdown in S&N's largest and fastest-growing division, orthopaedics. The demand for replacement joints has surged because of the ageing population and improvements in product design, but there have been more cautious comments recently from S&N's rivals, Zimmer and Stryker. They have suggested that competition is getting tougher.
S&N shares had fallen 4 per cent earlier this week on fears that the growth of the orthopaedics market had peaked. The company said its US sales of artificial joints grew 18 per cent in the last three months, compared with 23 per cent in the first quarter, but it was still outperforming the market as a whole. It characterised the latest quarter as a "blip" and Sir Christopher said: "We can argue over whether the US market is up 12 per cent or 13 per cent, but the fundamentals haven't changed. Artificial joints is a growing market."
Overall, S&N's sales in the first half of 2004 were up 6 per cent to £609.2m, held back by the weak dollar. Pre-tax profits were 22 per cent higher at £119.4m.
Analysts are forecasting about £260m for the year as a whole and some suggested the company could now struggle to recover lost ground. "They have left themselves with a hell of a lot to do," Seb Jantet, of Investec Securities, said.
Others who met the company, though, were confident new product launches will push up the full-year numbers. Peter Cartwright, of Williams de Broe, said: "Our questioning was sceptical, maybe even hostile...but they gave sensible answers and their confidence for the second half looks plausible."
- 1 Amy Winehouse statue unveiled in Camden
- 2 Lego breaks out of the toy box and heads for the gallery
- 5 A bottle of wine a day is not bad for you and abstaining is worse than drinking, scientist claims
George Galloway on Scottish independence: The political class is doing what Hitler couldn’t – destroying Britain
Daniele Watts: Django Unchained actress detained in Los Angeles after being mistaken for a prostitute
Scottish independence: Nationalist leader Jim Sillars threatens pro-union companies with 'day of reckoning' after independence
Scottish independence: Yes campaign feels the heat as Alex Salmond's NHS claims come under furious attack
Scottish independence: Britain faces 'constitutional crisis' at next election
£23m Birmingham cycle scheme is attacked by Tory councillor for not catering to the elderly
iJobs Money & Business
£280 - £320 per day: Ashdown Group: The Ashdown Group have been engaged by a l...
£400 - £450 Per Day: Clearwater People Solutions Ltd: **URGENT CONTRACT ROLE**...
£35000 - £38000 per annum + Benefits: Ashdown Group: Training Coordinator / Pl...
Data Governance Manager (Solvency II) – Contract – Up to £450 daily rate, 6 month (may go Permanent)
£400 - £450 Per Day: Clearwater People Solutions Ltd: We are currently looking...